Following the approval of a new drug developed by Eisai in Japan in collaboration with an American pharmaceutical company as a treatment for Alzheimer's disease by the US FDA (Food and Drug Administration), the Tokyo stock market on the 9th continued on the 8th. As a result, Eisai's stock was flooded with buy orders, and the price rose to the "stop height" level, which is the upper limit of the daily price increase for the second consecutive day, and the transaction was closed.
Eisai's stock was inundated with buy orders on the 9th following the 8th, and the sale was not completed due to the small number of sell orders, and the price was not priced in the morning transaction.
After that, at the end of the transaction time, the transaction was closed at the level of "stop height" which is the upper limit of the daily price increase, and Eisai's stock price was set at 10,755 yen, which is 1504 yen higher than the closing price on the 8th. I did.
Market officials said, "For new drugs, the US FDA will conduct additional clinical trials and may revoke approval if it does not work, but many investors are positive at this point. , Expectations are far ahead. "